Genetic silencing of MET markedly attenuated cancer cell migration capacity, concomitant with downregulation of epithelial–mesenchymal transition (EMT)-related signaling molecules and diminished activation of both STAT3 and ERK pathways. This evidence concerns the gene MET and cancer.